期刊
AMERICAN JOURNAL OF TRANSPLANTATION
卷 21, 期 5, 页码 1825-1837出版社
ELSEVIER SCIENCE INC
DOI: 10.1111/ajt.16369
关键词
clinical research; practice; infectious disease; infection and infectious agents ‐ viral; antibiotic; antiviral; clinical decision‐ making; complication; infectious
资金
- Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III [CP 18/00073]
This study reported the experience of solid organ and hematopoietic stem cell transplant recipients diagnosed with COVID-19 in Spain until July 13, 2020. The incidence of COVID-19 in transplant recipients was higher than the general population. Most patients required hospitalization, and adjusting immunosuppression could improve survival rates. Risk factors for death included age, lung transplantation, and hospital-acquired COVID-19.
We report the nationwide experience with solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients diagnosed with coronavirus disease 2019 (COVID-19) in Spain until 13 July 2020. We compiled information for 778 (423 kidney, 113 HSCT, 110 liver, 69 heart, 54 lung, 8 pancreas, 1 multivisceral) recipients. Median age at diagnosis was 61 years (interquartile range [IQR]: 52-70), and 66% were male. The incidence of COVID-19 in SOT recipients was two-fold higher compared to the Spanish general population. The median interval from transplantation was 59 months (IQR: 18-131). Infection was hospital-acquired in 13% of cases. No donor-derived COVID-19 was suspected. Most patients (89%) were admitted to the hospital. Therapies included hydroxychloroquine (84%), azithromycin (53%), protease inhibitors (37%), and interferon-beta (5%), whereas immunomodulation was based on corticosteroids (41%) and tocilizumab (21%). Adjustment of immunosuppression was performed in 85% of patients. At the time of analysis, complete follow-up was available from 652 patients. Acute respiratory distress syndrome occurred in 35% of patients. Ultimately, 174 (27%) patients died. In univariate analysis, risk factors for death were lung transplantation (odds ratio [OR]: 2.5; 95% CI: 1.4-4.6), age >60 years (OR: 3.7; 95% CI: 2.5-5.5), and hospital-acquired COVID-19 (OR: 3.0; 95% CI: 1.9-4.9).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据